Use of immune checkpoint inhibitor (ICI) therapy for cancer was associated with a significant reduction in actinic keratoses ...

Epigenetic inhibitors as a promising new antimalarial intervention strategy? A new study identifies an inhibitor of gene ...

In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of ...

Tuberculosis (TB) is a serious infectious disease caused by the bacterium Mycobacterium tuberculosis. While multidrug treatment regimens are the standard of care, the lengthy treatment schedule and ...

Panelists discuss how the Bayesian network meta-analysis showed which Janus kinase (JAK) inhibitors were most effective in ...

For patients with rheumatoid arthritis and inadequate response to JAK inhibitors, cycling to another JAK inhibitor is a more ...

Analysis by Mount Sinai researcher from First-of-its kind global trial could lead to future therapies to prevent deadly ...

Celcuity's gedatolisib, a dual PI3K/mTOR inhibitor, shows promise in Phase 3 breast cancer trials. Click here to read an ...

Kathryn Beckermann, MD, PhD, discusses the patient-reported outcomes for tivozanib plus nivolumab from the phase 3 TiNivo-2 ...

Esperion Therapeutics has two approved LDL-C lowering therapies, Nexletol and Nexlizet, but lacks a strong pipeline for future growth.